

日期: 2021/09/28 星期二

台灣時間	會議室	主題
17:30-19:00	Madrid Hall	OP 04 GLP-1 receptor agonism: higher dose, combination therapy, or both?
19:15-20:45	London Hall	OP 09 SGLT2 inhibitor trials
	Barcelona Hall	OP 11 Cardiac complications: mechanisms and possible treatments
	Saint Petersburg Hall	OP 12 The long and winding road to prevention and treatment of diabetes
19:00-21:00	Berlin Hall	Towards heart failure and cardiometabolic management in Type 2 diabetes
21:00-22:00	Moscow Hall	Lecture: Personalising the treatment for patients with type 2 diabetes: the mean is meaningless
	Paris Hall	Lecture: Diabetes remission through insulin secretion by islet non-beta cells

日期: 2021/09/29 星期三

台灣時間	會議室	主題
16:00-17:30	Moscow Hall	EASD/ADA Symposium: Optimising diabetes diagnosis, prevention and care: Is precision medicine the answer?
	Madrid Hall	Hypoglycaemia: unanswered questions
	Barcelona Hall	The liver, heart and kidney triangle: linking major organs in the complications of dysglycaemia
	Rome Hall	EASD/AASD Joint Symposium: Medical nutrition therapy, physical activity and exercise for diabetes
17:45-19:15	Madrid Hall	OP 16 CKD in diabetes - a costly complication
	Barcelona Hall	OP 17 Don't stop moving: beneficial effects of exercise on diabetes and beyond
19:30-20:30	Berlin Hall	DESG Symposium: Therapeutic patients' education - One year experience during COVID-19 pandemic
19:30-21:00	Moscow Hall	OP 19 Diet and nutrition
21:15-22:15	Rome Hall	New data from Dapa-CKD
22:30-23:30	Paris Hall	SARS-CoV-2 in human islets: a diabetes epidemic in the making?
	London Hall	Adipose tissue as a therapeutic target in type 2 diabetes: What should we aim for?
	Barcelona Hall	100 years Insulin treatment
	Saint Petersburg Hall	It is time to be active
	Rome Hall	Results from TriMASTER: a 3-way cross-over trial of precision medicine strategy of 2nd/3rd line therapy in type 2 diabetes

日期: 2021/09/30 星期四

台灣時間	會議室	主題
16:00-17:30	Moscow Hall	Prediabetes: Does it really matter?
	Paris Hall	EASD/ESC Symposium: How come not every patient with diabetes develops vascular complications?
	London Hall	Perspectives of the diabetic foot syndrome
	Saint Petersburg Hall	5 years of cardiovascular benefits of GLP-1 receptor agonists: evidence from recent cardiovascular outcomes trials
	Rome Hall	EASD/ESE Symposium: Diabetes and bone
	Athens Hall	Next step in incretin therapy: from single to dual agonism
17:45-19:15	London Hall	OP 27 Prediction tools for outcomes in diabetes
19:30-21:00	Paris Hall	OP 32 Benefits of GLP-1: from traditional to non-traditional complications
	Saint Petersburg Hall	OP 36 Optimising insulin therapy
22:15-23:15	Paris Hall	The future of incretin-based treatments
	Madrid Hall	Devices support diabetes treatment
	Barcelona Hall	Small vessels, big problems: cerebral small-vessel disease - a potential microvascular complication of diabetes
	Athens Hall	EMPEROR Preserved Study

日期: 2021/10/01 星期五

台灣時間	會議室	主題
16:00-17:00	Paris Hall	Current guidelines on diabetes management
	Madrid Hall	Debate: Preventing diabetic complications – 100 years on from insulin: Which of the newer classes will prevail?
	Barcelona Hall	In-hospital management of hyperglycaemia: still a Cinderella of diabetes management?
	Saint Petersburg Hall	COVID-19 infection in people with diabetes: a risky combination
	Rome Hall	EASD-Lancet Symposium: Treatment of obesity: the future of diabetes treatment?
17:15-18:45	Rome Hall	Finerenone: a new approach to kidney protection in patients with type 2 diabetes
17:15-18:15	Saint Petersburg Hall	OP 42 Cardiovascular disease: predictors and outcomes
19:45-21:15	Moscow Hall	Management of type 1 diabetes: ADA-EASD Consensus Report 2021
	Paris Hall	Going to bed with diabetes
	Saint Petersburg Hall	Major results from the Glycaemia Reduction Approaches in Diabetes: a Comparative Effectiveness (GRADE) Study
	Rome Hall	A novel approach to problematic hypoglycaemia: the HARPdoc RCT